Successful treatment of subcutaneously disseminated aspergillosis with caspofungin acetate in an allogeneic peripheral blood stem cell transplantation patient.
We present a patient with acute myeloid leukaemia who developed subcutaneously disseminated aspergillosis after allogeneic peripheral stem cell transplantation (PSCT). Disseminated aspergillosis after stem cell transplantation has a high mortality despite treatment with amphotericin B or one of the azoles. Aspergillosis in our patient was refractory to amphotericin B and itraconazole but was successfully treated with caspofungin acetate.
Chamuleau
M E D
ME
Department of Haematology, VU University Medical Centre De Boelelaan, Amsterdam, The Netherlands.
Deenik
W
W
Zweegman
S
S
Jonkhoff
A R
AR
Zaaijer
H L
HL
Janssen
J J W M
JJ
D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy* / Q000209:etiology; D000077336:Caspofungin; D004351:Drug Resistance; D054714:Echinocandins; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000150:complications / Q000628:therapy; D055666:Lipopeptides; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D010456:Peptides, Cyclic; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects*; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010455:Peptides; D010456:Peptides, Cyclic; D000077336:Caspofungin